Reviewer's report

Title: Update on the NCEP ATP-III Emerging Cardiometabolic Risk Factors

Version: 1

Date: 12 April 2014

Reviewer: Patrick Dessein

Reviewer's report:

This is a timely update on the relevant background of emerging cardiometabolic risk factors that may be included in future recommendations on cardiovascular risk stratification and management. The authors are well positioned in this regard and the manuscript reads well. I have the following minor essential suggestions/revisions.

It is suggested to include a comment on how the literature was perused. Which search engine(s) and key words were employed, and how were articles selected?

In the first paragraph on apolipoprotein B, I would consider including a comparison with total cholesterol/HDL cholesterol.

In the last paragraph on apolipoprotein B, line 5 and 6 of the respective page, 'hypertriglyceridemic' should be replaced by 'hypertriglyceridemia' (3 times). In the last paragraph on lipoprotein (a), first sentence, please include the reference.

In the section on pro-inflammatory factors, it may help to include that methotrexate as antiinflammatory therapy is associated with reduced cardiovascular risk in rheumatoid arthritis even when this is a high grade inflammatory disease.

In the first paragraph on subclinical ASCVD, first sentence, please include a reference.

Regarding several of the references, the journals are cited using only small case rather than capital letters.

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No competing interests.